Lundbeck Explored Potential Acquisition of Xeris Biopharma
The Danish pharmaceutical giant has reportedly held internal discussions regarding a takeover of the Chicago-based firm.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Do you believe pharmaceutical industry mergers generally result in better outcomes for patients?
Danish drugmaker Lundbeck has begun exploring a potential acquisition of Chicago-based Xeris Biopharma. The move follows reports that Lundbeck is working with financial advisers to facilitate a deal.
Why it matters
The acquisition would unite Lundbeck's focus on psychiatric and neurological disorders with Xeris' specialized portfolio of therapies for endocrine and rare neuromuscular conditions.
Xeris Biopharma reported second-quarter revenue of $91 million and currently holds a market capitalization of $1.79 billion. The company maintains three commercially available drugs, including Recorlev, Gvoke, and Keveyis.
The players
Lundbeck
A Denmark-based pharmaceutical company that focuses on developing therapies for psychiatric and neurological disorders.
Xeris Biopharma
A Chicago-based pharmaceutical company that focuses on developing therapies for endocrine and rare neuromuscular conditions.
The details
Lundbeck is reportedly leveraging external advisers to weigh a takeover of the Illinois company to bolster its existing treatment pipeline. Xeris specializes in complex endocrine and neuromuscular therapeutics, providing a potential expansion path for the Danish firm's neurological and psychiatric business units.
Timeline
Xeris reported second-quarter revenue of $91 million in August 2026.
Lundbeck reported stronger-than-expected second-quarter sales in August 2026.
Bloomberg News reported the potential takeover interest on September 29, 2026.
Market Landscape
This potential acquisition follows the broader industry pattern of global pharmaceutical companies acquiring smaller, specialized biopharma firms to diversify their treatment portfolios. Such moves allow larger firms like Lundbeck to integrate niche therapies into established global distribution networks.
For patients and healthcare providers, the acquisition could eventually influence the accessibility and distribution of Xeris drugs like Gvoke and Recorlev. Customers should monitor potential changes to manufacturer support programs or supply chain logistics following any finalized deal.
The takeaway
Market participants often view such potential takeovers as indicators of consolidation within specialized biopharma segments. Investors and patients should track official filings from both companies for confirmation of any structural business shifts.
Further reading
For more updates on local medical industry shifts, visit our Healthcare section.
Live Poll
Do you believe pharmaceutical industry mergers generally result in better outcomes for patients?
